Stock Ratings / Health Care / RCKT / dividends

GLSI (41) LRMR (50) LYEL (38) BIOA (44) ⌘ Pro Terminal →

Rocket Pharmaceuticals Inc. (RCKT) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Is RCKT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $2.54 (-1.55% 1D, market cap $278.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RCKT ranks #920 in composite RQD confidence.

Q: How does RCKT compare to GLSI and LRMR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RCKT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GLSI (Greenwich LifeSciences Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $278.9M) and LRMR (Larimar Therapeutics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $277.4M). Among the 5-stock peer group, RCKT leads on earnings multiple (N/A) while RCKT leads on capital efficiency (-35.0% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for RCKT?

Per RCKT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001281895), Rocket Pharmaceuticals Inc. generated $0 in revenue, -$223.1M in net income, and -$190.5M in free cash flow against $330.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is RCKT trading relative to its 50-day, 200-day, and 52-week technical levels?

RCKT last traded at $2.54 (-1.55% on volume of 1,830,123 shares), positioning the stock -14.19% below its 50-day simple moving average ($2.96) and -26.38% below its 200-day simple moving average ($3.45). Across its 52-week range of $2.17 to $5.45, RCKT sits at the 11.3% percentile with a 14-day RSI of 45.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.22 to $2.86).

Q: Does RCKT pay a dividend and is it safe?

Rocket Pharmaceuticals Inc. (RCKT) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$2.54 -1.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.53

Rocket Pharmaceuticals Inc. (RCKT) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $278.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.53 (-0.47%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RCKT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY RCKT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (32% of score)

FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 45.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (23% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.56-14.8% Next Q

Q2 (-2Q)

Grade E$2.18+5% Next Q

Q3 (-1Q)

Grade E$2.29+10.9% Next Q

Current

Grade E$2.54-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RCKT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RCKT currently carries a cautious 31/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.96) and Max Pain ($2.67) forces dealer call-delta covering toward $5.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RCKT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RCKT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RCKT)

✓Walkthrough of RCKT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RCKT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.01%▼ DESCENDING CHANNEL

2026-10-30O $2.50H $2.57L $2.37C $2.54VOL 1.53M

RES: $3.57SUP: $2.02SMA50: $2.96SMA200: $3.45

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RCKT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RCKT Butterfly Map → + Track RCKT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RCKT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RCKT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RCKT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RCKT)

Health Care Rank #920 of 1016 ⚔️ GLSI vs RCKT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RCKT vs. GLSI, LRMR, LYEL, BIOA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rocket Pharmaceuticals Inc. (RCKT) ranks #920 by composite RQD confidence (31/100, grade E) and #529 by equity capitalization ($278.8M). Within this direct 5-issuer industry benchmark cohort, RCKT leads on earnings valuation at N/A trailing P/E, while RCKT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LRMR currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with RCKT at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RCKT ACTIVE Rocket Pharmaceuticals Inc.	E	31/100	—	—	-35.0%	-1.55%	$278.8M	Benchmark Subject
GLSI Greenwich LifeSciences Inc.	D-	41/100	—	—	-35.0%	+3.77%	$278.9M	/glsi-vs-rckt →
LRMR Larimar Therapeutics Inc.	D	50/100	—	—	-35.0%	+5.12%	$277.4M	/lrmr-vs-rckt →
LYEL Lyell Immunopharma Inc.	D-	38/100	—	—	-35.0%	+3.43%	$277.0M	/lyel-vs-rckt →
BIOA BioAge Labs Inc.	D	44/100	—	—	-35.0%	0.00%	$272.6M	/bioa-vs-rckt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001281895

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rocket Pharmaceuticals Inc. (RCKT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$223.1M, operating cash flow of -$190.0M, and free cash flow of -$190.5M (+11.7% YoY). On the balance sheet, RCKT closed FY2025 with $330.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$223.1M	-$190.0M	-$190.5M	$330.4M	—
FY2024 (FY)	2024-12-31	$0	-$258.7M	-$209.7M	-$215.6M	$527.7M	—
FY2023 (FY)	2023-12-31	$0	-$245.6M	-$194.9M	-$194.9M	—	—

3. RCKT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RCKT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Rocket Pharmaceuticals Inc. (NASDAQ: RCKT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $2.54 (-1.55% 1D, market cap $278.8M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RCKT ranks #920 in composite RQD confidence.

How does RCKT compare to GLSI and LRMR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RCKT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GLSI (Greenwich LifeSciences Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $278.9M) and LRMR (Larimar Therapeutics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $277.4M). Among the 5-stock peer group, RCKT leads on earnings multiple (N/A) while RCKT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RCKT?

Per RCKT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001281895), Rocket Pharmaceuticals Inc. generated $0 in revenue, -$223.1M in net income, and -$190.5M in free cash flow against $330.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RCKT trading relative to its 50-day, 200-day, and 52-week technical levels?

RCKT last traded at $2.54 (-1.55% on volume of 1,830,123 shares), positioning the stock -14.19% below its 50-day simple moving average ($2.96) and -26.38% below its 200-day simple moving average ($3.45). Across its 52-week range of $2.17 to $5.45, RCKT sits at the 11.3% percentile with a 14-day RSI of 45.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.22 to $2.86).

RCKT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does RCKT pay a dividend and is it safe?

Rocket Pharmaceuticals Inc. (RCKT) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: RCKT RQD Cockpit RCKT 12M Forecast RCKT Earnings & Move RCKT Dividends & DRIP RCKT Insiders & 13F RCKT Whale Options RCKT Profit Sankey RCKT News & Why